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Abstract: In ∼30% of epileptic patients, full seizure control is not possible, which is why the 
search for novel antiepileptic drugs continues. Retigabine exhibits a mechanism of action that 
is not shared by the available antiepileptic drugs. This antiepileptic enhances potassium currents 
via Kv7.2–7.3 channels, which very likely results from destabilization of a closed   conformation 
or stabilization of the open conformation of the channels. Generally, the pharmacokinetics of 
retigabine are linear and the drug undergoes glucuronidation and acetylation. Results from 
clinical trials indicate that, in the form of an add-on therapy, retigabine proves an effective drug 
in refractory epileptic patients. The major adverse effects of the add-on treatment are dizziness, 
somnolence, and fatigue. This epileptic drug is also considered for other conditions – neuropathic 
pain, affective disorders, stroke, or even Alzheimer’s disease.
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Introduction
Experimental data indicate that epileptic seizures may be associated with an imbalance 
between inhibitory (represented mainly by the γ-amino butyric acid [GABA]-ergic 
system) and excitatory neurotransmission, mediated in general by glutamate in the 
central nervous system (CNS).1 The only exception appears to be absence seizures, 
probably resulting from an excess of GABA-ergic inhibition, causing 3 Hz oscillations 
in the thalamus.1 Still, the majority of epileptic seizures depend upon a reduced 
inhibition and excessive stimulation, and the existing antiepileptic drugs, including both 
classical and newer ones, through the targeting of the inhibitory or excitatory events 
restore the proper balance. Some of the drugs enhance GABA-mediated inhibition 
via a direct or indirect influence on GABAA receptors. Direct GABA enhancers, 
modulating diverse binding sites on the GABAA receptor complex, are benzodiazepines 
(diazepam, clonazepam), felbamate, phenobarbital, topiramate, and stiripentol.1–3 
Other antiepileptics reduce the synaptic GABA uptake (tiagabine) or increase the 
synaptic GABA concentration through the inhibition of its catabolism (valproate or 
vigabatrin).1,2 Also, antiepileptic drugs may reduce glutamate-mediated excitation 
via a direct blockade of ionotropic glutamate receptors. For instance, phenobarbital 
or topiramate are α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor blockers,2 and recently, such an activity was ascribed to lamotrigine.4 On 
the other hand, felbamate has been documented to effectively block N-methyl-D-
aspartate (NMDA) receptors through its potent affinity to the NR2B subunit.5 Certainly, 
some antiepileptic drugs can sufficiently reduce glutamate excitation indirectly. 
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For example, carbamazepine, lamotrigine, oxcarbazepine, 
and topiramate in the range of concentration of 150–1500 µM 
progressively inhibit veratridine-induced glutamate release 
from the hippocampal nerve endings,6 whilst carbamazepine, 
oxcarbazepine, and phenytoin (500–1500 µM) have been 
found effective against high potassium-induced glutamate 
release in the same experimental model.7 Felbamate has 
been documented to inhibit glutamate release in the rat 
entorhinal cortex, an effect very likely dependent on 
the blockade of presynaptic NMDA receptors.8 Many 
antiepileptic drugs control seizure activity through their 
blockade of voltage-operated sodium or calcium channels. 
Carbamazepine, lamotrigine, oxcarbazepine, phenytoin, 
topiramate, and valproate are effective sodium channel 
blockers.9 Ethosuximide and valproate reduce calcium 
currents via T-type channels, which is probably responsible 
for their anti-absence activity.2 L-type calcium channels are 
blocked by carbamazepine and topiramate; N-type channels, 
by levetiracetam; N- and P/Q-type, by gabapentin and 
pregabalin; N-, P-, and T-type channels, by zonisamide; and 
N-, P/Q-, R-, and T-channels, by lamotrigine.9
Epilepsy as a serious neurologic disorder affects circa 
50 million people worldwide, which amounts to about 1% 
of the population.1,10 Seizures, whose frequency differs 
considerably between patients, distinctly deteriorate qual-
ity of life.11 Although antiepileptic drugs remain the main 
therapeutic option for the management of epilepsy,11 there 
are around 25%–30% of cases that do not fully respond 
to pharmacotherapy.1 From what was stated above, it is 
evident that both classical (carbamazepine, ethosuximide, 
phenytoin, p  henobarbital, valproate) and newer (gabapentin, 
lamotrigine, oxcarbazepine, tiagabine, topiramate, or 
vi  gabatrin) antiepileptic drugs share similar mechanisms of 
action, affecting in comparable ways inhibitory and excitatory 
neurotransmissions or voltage-dependent ion channels.1,2 
The main advantage of newer antiepileptics is that they exert 
milder adverse effects, their protective potential being of the 
same potency as that of classical antiepileptic drugs.1,2,12 The 
mechanism of action of only one newer antiepileptic drug, 
levetiracetam, is somewhat different from the battery of 
mechanisms listed above. Levetiracetam binds to the synaptic 
vesicle protein SV2A, which results in the modulation of 
neurotransmitter release.13
A question arises whether antiepileptic drugs may take 
advantage of alternative mechanisms which can provide 
effective anticonvulsant activity along with the beneficial 
adverse profile. Retigabine (known as ezogabine in the 
United States), an antiepileptic drug sharing a completely 
different mechanism of action, is a good example of the 
search for completely novel antiepileptic drugs.
Structure and metabolites  
of retigabine
Chemically, retigabine is an N-(2-amino-4-(4-fluoroben-
zylamino)phenyl carbamic acid ethyl ester. The drug 
is subject to glucuronidation in humans and dogs, with 
the formation of two N-glucuronides: the N2- and the 
N4-glucuronide. The former metabolite prevails.14,15
Pharmacodynamics
Retigabine, apart from its completely novel mechanism of 
action involving an enhancement of potassium currents, 
is also a GABA enhancer. Specifically, the drug has been 
proved to potentiate GABA-produced chloride currents in 
rat cortical neurons, and this very effect was evident for a 
relatively low concentration of retigabine, which amounted 
to 10 µmol.16 However, the involvement of benzodiazepine 
receptors in this effect is unlikely, because flumazenil did 
not block this particular action of retigabine.16 Nevertheless, 
both retigabine and GABA enhance their binding to the 
GABAA receptor complex and are capable of displacing a 
GABAA receptor tracer ligand,17 which may suggest retiga-
bine interaction with the GABAA receptor at a place different 
from the benzodiazepine receptor. Apart from the receptor 
interactions, the synthesis of GABA has been elevated by 
retigabine in rat hippocampal slices.18
As already mentioned above, retigabine is a modulator of 
potassium currents. Kv7 potassium channel (formerly known 
as KCNQ channel) is composed of five subunits, and apart 
from the Kv7.1, the remaining subunits (Kv7.2–7.5) are pres-
ent in the nervous system.19 These four subunits conduct the 
low-threshold voltage-gated potassium current and form the 
“M-channel.” In most neurons, the M-channel is mainly com-
posed of Kv7.2–7.3 subunits.19 Retigabine has been found as 
an effective potassium channel opener. The specificity of this 
effect is of great magnitude as this antiepileptic drug is still 
effective in this regard in as low concentration as 0.1 µmol.20 
The opening of the potassium channels by retigabine and the 
subsequent hyperpolarization in rat hippocampal-entorhinal 
slices is very likely to result from this specific effect.21 Further 
studies on the retigabine (0.1–10.0 µmol)-induced neuronal 
outward current have revealed that this drug considerably 
potentiates Kv7.2–7.3 currents, and this particular action is 
probably related to destabilization of a closed conformation 
or stabilization of the open conformation of the Kv7.2–7.3 
channels.22 The Kv7.2–7.3 channel blocker, linopridine 
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(at 10 µmol) inhibits retigabine-induced outward potassium 
channels.22
The retigabine’s mechanism of action and that of some 
reference antiepileptic drugs is displayed in Table 1.
Pharmacokinetics and metabolism
In contrast to the majority of classical and some newer 
antiepileptic drugs, retigabine does not undergo any hepatic 
metabolism via cytochrome P-450 enzymes.23 Primarily, the 
drug is subject to glucuronidation to form N-glucuronide 
metabolites or to acetylation, which results in its conversion 
to mono-acetylated metabolite – AWD21-360.23,24 Human 
or dog metabolism of retigabine is mainly dependent on 
glucuronidation; whilst in rats, there are a couple of dif-
ferent metabolic pathways forming multiple metabolites 
of this antiepileptic drug.24 In humans and dogs, there is 
a constant ratio between unmetabolized retigabine and its 
N-glucuronide.14 The constant ratio may be indicative of 
a coupling between concentrations of retigabine and its 
metabolite through enterohepatic circulation and reactions 
of glucuronidation/deglucuronidation.14 In healthy volunteers 
on an oral daily dose of 600 mg of retigabine, evaluation of 
samples of plasma and urine have provided evidence on the 
existence of two metabolic pathways – glucuronidation and 
acetylation.23
Within the dose range of the first dose (100–350 mg and 
then twice daily for a fortnight), retigabine’s pharmacoki-
netics were linear and dose-dependent when evaluated in 
healthy white and black volunteers.25 After a single dose of 
200 mg, a rapid absorption was noted, the mean maximum 
plasma concentration reaching 819 ng/mL within the mean 
time of 1.6 hours. In white volunteers, the mean apparent ter-
minal half-life was 8 hours with the accompanying apparent 
  clearance of 0.70 L × h−1 × kg−1; whilst in the black volunteers, 
the respective parameters were 25% and 30% lower.25
Similar results have been documented by Hermann et al,15 
who after a single dose of the antiepileptic in young men 
aged 18–40 years, estimated the mean terminal half-life of 
8.5 hours with the apparent clearance of 0.67 L × h−1 × kg−1. 
However, the mean maximum concentration was consider-
ably lower (420 ng/mL), and the time to reach it was some-
what longer (2 hours).15
There are also data available on the effects of some other 
antiepileptic drugs on the pharmacokinetic parameters of 
retigabine in healthy volunteers. As regards to phenobarbital, 
this antiepileptic did not modify pharmacokinetics of 
retigabine, indicating that phenobarbital is likely to possess 
no influence on the retigabine’s metabolism.26 When combined 
with lamotrigine in healthy subjects, the retigabine’s clearance 
was reduced by 13%, and its mean half-life as well as area 
under the plasma concentration–time curve were increased by 
7.5% and 15%, respectively.27 These authors present the view, 
that a competition between both drugs for renal excretion, 
but not for glucuronidation, might explain this interaction.27 
They have also examined an impact of retigabine on the 
pharmacokinetics of lamotrigine, proving that lamotrigine’s 
metabolism is enhanced to a moderate degree – its apparent 
clearance being increased by 22%, and its mean half-life 
along with the area under the plasma concentration–time 
curve reduced by 15% and 18%, respectively. The authors of 
that study27 are of the opinion that this interaction is not likely 
to result from the induction by retigabine of metabolizing 
enzymes because this antiepileptic was without any significant 
influence upon the pharmacokinetics of carbamazepine, 
phenobarbital, phenytoin, topiramate, and valproate in 
epileptic patients.26,28
Table 1 Mechanisms of action of RTG compared with those of other AEDs: vPA, LTG, TPM, OXC, CBZ, TGB, vGB, and GBP
AEDs Enhancement of GABA- 
mediated inhibition
Inhibition of  
glutamate excitation
Blockade of  
calcium channels
Blockade of  
sodium channels
Enhancement of  
potassium currents
RTG + NE NE NE +
vPA +/− + + (T-type) +/− NE
LTG NE + + (N, P/Q, R, T) + NE
TPM + + + (L) + NE
OXC NE NE + (N, P) + NE
CBZ NE NE + (L) + NE
TGB + NE NE NE NE
vGB + NE NE NE NE
GBP + NE + (N, P/Q) NE NE
Notes: +, well documented mechanism of action; NE, not effective at therapeutic AED concentrations; +/−, controversial results. Data are from Czuczwar and Patsalos,1 
Czapinski et al,2 Sitges et al,6 Sitges et al,7 and Perucca.9
Abbreviations: AED, antiepileptic drug; CBZ, carbamazepine; GABA, γ-amino butyric acid; GBP, gabapentin; LTG, lamotrigine; OXC, oxcarbazepine; RTG, retigabine;   
TGB, tiagabine; TPM, topiramate; vGB, vigabatrin; vPA, valproate.
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Activity and toxicity  
in experimental models of epilepsy
Retigabine is effective in a variety of experimental 
models of epileptic seizures – the drug inhibits maximal 
electroshock-, pentylenetetrazol-, N-methyl-D-aspartate-, 
kainate-, picrotoxin-, and sound-induced seizure activity 
in rodents.13 Also, in doses producing no or mild adverse 
effects, retigabine is effective in elevating the after-discharge 
threshold and reducing the after-discharge duration in fully 
hippocampal-kindled rats.29 Remarkably, retigabine in three 
age groups of young rats (P14, P21, and P35) was capable of 
inhibiting the evolution of kindling to the maximum stage, 
and in one group (P14), it distinctly delayed the acquisition 
of focal convulsions. These data may lead to a conclusion 
that apart from the apparent anticonvulsant activity, retigabine 
possesses an antiepileptogenic potential as well.29 It is 
remarkable that the developmental profile of another potent 
antiepileptic drug, topiramate, was quite distinct in that 
this drug, in contrast to retigabine, was least effective in 
P14 rats.30 Nevertheless, retigabine was much weaker as an 
anticonvulsant in mutant Sz1 mice that were deprived of most 
of the C-terminus in their Kv7.2 channels, whilst its potent 
anticonvulsant activity against partial psychomotor seizures 
was not affected in the littermate control.31
Retigabine does not exert any harmful activity upon 
reproductive functions in rats, and no teratogenic potential of 
this antiepileptic has been found in rats or rabbits.32 Perinatal 
or postnatal treatment with retigabine is not associated with 
any developmental toxicity, the only exception being the 
animals injected with the highest dose of this antiepileptic 
drug, whose growth is significantly reduced.32
Acute toxicity evaluations have revealed that in different 
animal species, retigabine induces a number of toxic effects, 
mainly derived from the CNS – hypo- or hyperkinesia, unco-
ordinated movements, tremor, stilted gait, and convulsions. 
However, electroencephalographic parameters were not 
affected by retigabine in isolated guinea-pig heart or in vivo 
in dogs (orally up to 38 mg/kg for a week).32
Interactions of retigabine  
with classical and newer 
antiepileptic drugs in mice
Combinations of retigabine with classical or newer 
antiepileptic drugs have been evaluated experimentally 
with the use of two methods. One method assumed the 
combined treatment of retigabine at subprotective doses 
with active doses of other antiepileptics. Based on this 
experimental approach, De Sarro et al33 have found that 
retigabine at 0.5 mg/kg potentiated the anticonvulsant 
activity of carbamazepine, diazepam, felbamate, lamotrigine, 
phenytoin, phenobarbital, and valproate against sound-
induced convulsions in DBA/2 mice. The most distinct 
reductions in the respective ED50 values were observed for 
diazepam, phenobarbital, phenytoin, and valproate. The 
protective indices for the combined treatments were better 
than that for retigabine alone. The observed interactions may 
be interpreted in terms of pharmacodynamic mechanisms, 
because in no case did retigabine change the total or free 
plasma concentrations of the studied antiepileptic drugs.33
With a method of isobolographic analysis, one can accu-
rately evaluate the final effects of a drug combination as 
synergistic, additive, or antagonistic.34 In the test of maximal 
electroshock in mice, the dose-effect curves for retigabine 
and valproate were parallel, so it was possible to assess 
their interaction in fixed-dose ratios other than just 1:1. It is 
noteworthy that in three dose ratios of 1:3, 1:1, and 3:1, the 
combination of retigabine + valproate proved synergistic 
against maximal electroshock in mice. However, the dose 
effects curves for retigabine and carbamazepine or lamotrig-
ine were not parallel, and consequently, only one fixed-dose 
ratio of 1:1 of these drugs could be evaluated. In both cases 
(retigabine + carbamazepine or retigabine + lamotrigine) 
additivity was noted against maximal electroshock-induced 
convulsions in mice. Neurotoxic evaluation has indicated that 
no evaluated combination was associated with disturbed 
motor coordination, long-term memory, or muscular strength. 
Determinations of the concentrations of all drugs in a given 
combined treatment have revealed that only in the fixed 
dose ratio of 3:1 (retigabine:valproate) combination, the free 
plasma and total brain levels of valproate were elevated.34
Clinical efficacy, safety,  
and tolerability
Initial clinical evidence indicated that retigabine both as 
mono- or polytherapy in 15 healthy volunteers was in prin-
ciple well tolerated. Headache was most frequently reported, 
and there were no laboratory test or ECG disturbances. The 
drug had to be withdrawn in one epileptic patient due to 
severe abdominal pain.26
Retigabine was subsequently studied as an add-on drug 
in patients with partial onset seizures within a Phase II mul-
ticenter, randomized, placebo-controlled clinical trial, being 
titrated to daily doses of 600, 900, and 1200 mg over a period 
of 2–6 weeks.35 The respective responder rates for these 
doses were 23%, 32%, and 33% versus 16% for placebo, 
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which reached the level of significance except for the dose 
of 600 mg. The most frequently reported adverse effects 
were somnolence, dizziness, confusion, speech disorder, 
vertigo, tremor, amnesia, abnormal thinking, abnormal gait, 
paresthesia, and diplopia.35
Finally, the drug was tested in two Phase III multicenter, 
randomized, double-blind studies in which retigabine was 
added to 1–3 antiepileptic drugs,32 and the results of these trials 
led to formal registration of the drug by the European Medi-
cines Agency and the Food and Drug Administration. The first 
study, sponsored by Valeant36 and registered as RESTORE 1 
assumed titration of this antiepileptic to 1200 mg. There were 
two periods of observation: an 8-week, prospective baseline 
phase and an 18-week double-blind treatment period (with 
6-week initial dose titration phase). Two primary endpoints 
were considered: percentage change in 28-day total partial 
seizure frequency between baseline and double-blind period, 
and responder rate, defined as 50% reduction in 28-day total 
partial seizure frequency between baseline and maintenance 
phase. A total of 306 patients were randomized, and 305 
of those were used in the intention-to-treat analysis. The 
retigabine treatment group had 44.3% reduction in monthly 
seizure frequency compared with 17.5% in the placebo group 
(P = 0.001). Responder rate was 44.4% in the treated group, 
while 17.8% in the placebo group (P = 0.001). During the 
maintenance phase, 5% of patients in the treated group were 
seizure-free compared with 1% in the placebo group, but the 
difference did not reach statistical significance. However, 
the percentage of seizure-free days in the treated group was 
significantly greater than in the placebo group. The propor-
tion of patients discontinuing due to treatment-emergent 
adverse events (TEAEs) was 26.8% (retigabine) versus 
8.6% (placebo). Dizziness, somnolence, fatigue, confusion, 
dysarthria, urinary tract infection, ataxia, and blurred vision 
were the most common TEAEs reported by more patients 
treated with retigabine than placebo.36 The second study, 
known as RESTORE 2, was also sponsored by Valeant.37 The 
study was designed with four phases: a prospective 8-week 
baseline, 4-week titration up to 600 mg/day or 900 mg/day, 
12-week maintenance, and a 4-week transition phase if 
patients elected to participate in the open-label extension 
phase. A total of 539 patients were randomized, and 538 
patients were included in the intention-to-treat analysis. 
The median percentage reduction was greater for both the 
600 mg/day (27.9%, P = 0.007) and 900 mg/day (39.9%, 
P = 0.001) treatment groups compared with placebo (15.9%). 
Responder rate defined as 50% reduction in seizure frequency 
was significantly higher in both the 600 mg/day (38.6%) 
and the 900 mg/day (47.0%) group than in placebo-treated 
patients (18.9%, P = 0.001). Treatment discontinuations 
due to adverse events (AEs) were more likely with retigabine 
than with placebo (placebo, 8%; 600 mg, 17%; 900 mg, 26%). 
The most commonly reported (.10%) AEs in the placebo, 
retigabine 600 mg/day and 900 mg/day groups were dose 
dependent and included dizziness (7%, 17%, 26%, respec-
tively), somnolence (10%, 14%, 26%), headache (15%, 11%, 
17%), and fatigue (3%, 15%, 17%).37
Except CNS-related effects, there is another issue which 
deserves special attention. There was some experimental 
evidence that retigabine had adverse effects on bladder 
function in a rat model. Investigators from RESTORE 1 and 
2 studies performed detailed evaluation of all possible adverse 
reactions from urinary tract in retigabine-treated patients. In 
RESTORE 2, three patients on retigabine reported chroma-
turia, and three patients complained of adverse events of the 
urinary tract (one nephritis and two urinary retention). The 
RESTORE 1 study revealed that 15 of the retigabine-treated 
patients had increased post-void residual volumes compared 
with six of the placebo-treated patients. Among other AEs 
reported were urinary tract infection, urinary hesitation, 
dysuria, and chromaturia. In general, the safety profile in 
both studies was good and no serious adverse effects were 
reported.
RESTORE 1 and 2 were actually randomized controlled 
short-term studies, and there are no results available as yet 
on long-term efficacy and safety of retigabine in epileptic 
patients.
Looking to the future, there are several clinical issues to be 
studied with regard to retigabine treatment in epilepsy patients. 
It would be very important to assess the clinical spectrum for 
different seizure types, especially absence, tonic-clonic, as well 
as myoclonic generalized seizures both in pediatric or adult 
populations, especially when used in newly diagnosed epilepsy. 
In addition, studies on the efficacy of retigabine in pediatric 
patients with partial-onset seizures or Lennox-Gastaut syn-
drome have been planned.32 There is experimental evidence 
that retigabine has broad anticonvulsant activity when used in 
various models of generalized seizures.38 Similarly, the efficacy 
and safety of the drug should be studied in special populations 
like elderly patients, women in child-bearing age, and patients 
with intellectual disability. Particular attention should be put on 
co-morbidities including diseases of the urinary tract, having in 
mind the known effects of the drug on urinary retention. Above 
aspects will definitely be taken up in future post-marketing 
studies to provide more data on possible applications of the 
drug in wide clinical practice.
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Nonepilepsy potential of retigabine
Antiepileptic drugs have been shown effective in conditions 
other than epilepsy, and their clinical use in neuropathic 
pain, migraine, affective disorders, spasticity, or restless legs 
syndrome has been approved.39 There are experimental data 
indicating that retigabine inhibits neuropathic pain in models 
of chronic constriction injury and spared nerve or in the for-
malin test.40,41 The drug is also likely to exert some antimanic 
activity as it distinctly counteracts enhanced locomotor activ-
ity by amphetamine + chlordiazepoxide in rats.42 Retigabine 
has also been proved to attenuate the psychostimulatory 
effects of cocaine, methylphenidate, or phencyclidine and 
thus may be considered as an anti-addictive drug.43 Other 
basic studies have provided evidence that retigabine actu-
ally exerts anxiolytic and antidystonic effects.44,45 Some case 
reports and even a clinical trial indicate that retigabine may 
delay the progression of Alzheimer’s disease.46,47 Possible 
nonepilepsy uses of retigabine are listed and compared with 
those of other antiepileptic drugs in Table 2.
Final considerations
Although many newer antiepileptic drugs have been available 
in the last two decades, the percentage of drug-resistant patients 
has not significantly improved.1,2,12 One possible reason for 
this apparent failure may be that newer antiepileptic drugs are 
usually added to the existing antiepileptic treatment in drug-
resistant patients. Thus, such a therapeutic approach is inde-
pendent of the existing treatment, and the antiepileptic drugs 
are combined randomly. Considering experimental data on the 
combined treatment, it is evident that the final outcome of a 
drug interaction may be synergy, additivity, or antagonism.48 
It would be thus reasonable to consider drug combinations 
exerting anticonvulsant synergy from both experimental48 
and clinical points of view.49 In this context, best therapeutic 
results with retigabine as an add-on drug, would be expected 
in its combination with valproate, which is purely synergistic.34 
Combinations of carbamazepine + retigabine or lamotrigine + 
retigabine might be less clinically effective.34
The adverse profile of retigabine is in fact the result of its 
interactions with the existing antiepileptic treatment. So far, 
there are no data available on the tolerability of retigabine 
applied in the form of monotherapy.
Some reports indicate that retigabine may exert neuroprotec-
tive effects in some brain areas (eg, pyriform cortex) in vivo after 
kainate-induced status epilepticus in rats.50 Also, there are data 
on its neuroprotective action in vitro.51 However, the significance 
of these findings in terms of epileptogenesis may be unclear 
since there is no distinct link between these two events.50
The research on positive potassium channel modulators is 
growing very fast. There is currently a compound available, 
which contrary to retigabine, may activate the mutated Kv7.2 
channel. This finding can actually broaden the practical utility 
of potassium channel activators.52
To date, there are several reviews devoted to retigabine 
(the last four being published in 2011).53–61 Whilst dealing 
with generally similar points (pharmacokinetics and pharma-
codynamics of retigabine along with its clinical efficacy and 
adverse effects), this review is also focused on the effective-
ness of retigabine in combinations with other antiepileptic 
drugs as well on its nonepilepsy potential, which is also 
mentioned by Weisenberg and Wong.59
Conclusion
Retigabine is the first antiepileptic drug able to enhance 
neuronal potassium currents, and this effect is blocked by the 
Kv7.2–7.3 channel blocker linopridine.22 This antiepileptic 
has shown a good experimental profile in interactions with 
valproate (anticonvulsant synergy) or carbamazepine and 
lamotrigine (anticonvulsant additivity).34
Clinically, in patients with refractory epilepsy, retigabine 
in the form of an add-on therapy, led to considerable 
improvement, reflected by a significant reduction in s  eizure 
Table 2 Nonepilepsy uses of RTG and other AEDs: CBZ, GBP, LTG, OXC, and TPM
AEDs* Nonepilepsy indications
Neuropathic 
pain
Bipolar 
disorder
Dystonia  Cocaine 
addiction
Alzheimer’s 
disease
RTG +a +a +a +a +a,b
CBZ +/− + +c +/− +
GBP + +/− +/− +/− +d
LTG + + −a +/− +d
OXC + +/− + + −
TPM +/− +/− + +/− +
Notes: +, drug effective; +/−, controversial data; −, drug ineffective; aexperimental data; binitial clinical data; cdystonia as a result of drug toxicity; dlimited number of patients. 
*All data are from references,39,62–79 except for RTG, which are from references.40–43,45–47
Abbreviations: AED, antiepileptic drug; CBZ, carbamazepine; GBP, gabapentin; LTG, lamotrigine; OXC, oxcarbazepine; RTG, retigabine; TPM, topiramate.
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frequency with an accompanying good tolerability profile.32,35 
There are also data available showing that the clinical use of 
retigabine may be considered also for nonepilepsy indi  cations 
(eg, neuropathic pain, mania, possibly bipolar disorder, 
stroke, and Alzheimer’s disease).40–42,46,47
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